Dr Reddy's Gets CDSCO Panel Nod To Import, Market Saccharomyces Boulardii, BE, CT Waived

Written By :  Dr. Divya Colin
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2025-06-15 07:00 GMT   |   Update On 2025-06-15 07:00 GMT
Advertisement

New Delhi: Granting the bioequivalence study waiver and clinical trial study waiver, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved Dr Reddy's Laboratories proposal to import and market of Saccharomyces Boulardii CNCM I-745, 250 mg/ 8 ml powder and solvent for oral suspension.

This came firm presented the proposal for import and market of Saccharomyces Boulardii CNCM I-745, 250 mg/ 8 ml powder and solvent for oral suspension for the

Advertisement

-Treatment of acute infectious diarrhoea in adults and children.

- Prevention and treatment of antibiotic associated colitis and diarrhoea.

- In addition to vancomycin/ metronidazole treatment to prevent recurrence of Clostridium difficile disease (CDD).

- Supportive in the treatment of diarrhea occurring in irritable bowel syndrome (IBS).

Along with justification for BE waiver and CT waiver before the committee.

The committee noted that Saccharomyces Boulardii 250 mg Sachets/ Capsules were already approved in India since 1997 and the applied product Saccharomyces Boulardii CNCM I-745, 250 mg/ 8 ml powder and solvent for oral suspension was approved in France, Hungary, Sweden and Bulgaria.

Saccharomyces boulardii for treating and preventing diarrhea, including rotaviral diarrhea in children. It's also used for other types of diarrhea, acne, a digestive tract infection that can lead to ulcers, and many other conditions, but there is no good scientific evidence to support many of its other uses.

At the recent SEC meeting for Gastroenterology and Hepatology held on 23rd May 2025, the expert panel reviewed the proposal for import and market of Saccharomyces Boulardii CNCM I-745, 250 mg/ 8 ml powder and solvent for oral suspension.

After detailed deliberation, the committee recommended for grant of permission for import and market of Saccharomyces Boulardii CNCM I-745, 250 mg/ 8 ml powder and solvent for oral suspension with bioequivalence study waiver and clinical trial study waiver.

Also Read: Revise Phase IV Protocol for Gliclazide-Sitagliptin FDC with Scientific Justification: SEC Tells Eris

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News